Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in HR-positive, HER2-negative Aromatase Inhibitor Resistant Metastatic Breast Cancer
Head to head comparison demonstrates progression-free survival advantage with chemotherapy over palbociclib plus endocrine therapy